Skip to main content

Table 1 Characteristics of the patients with CR GNB

From: Infection control management and surveillance of carbapenem-resistant Gram-negative bacteria in hematopoietic stem cell recipients

Case Species Antibiotic resistance phenotypea Carbapenemaseb First acquisition on the HSCT unit Colonization Subsequent infection with the colonizing CR GNB Antibiotic treatment of infection Decolonization procedure
1 Escherichia coli Piperacillin/Tazobactam: R
Ceftazidime: R
Fluroquinolones: R
Gentamicin: R
Meropenem: I (8)
Ertapenem: R (> 2)
Imipenem: I (4)
Colistin: S
Ceftazidime/Avibactam: S
Ceftozolan/Tazobactam: S
Not detected Yes (after HSCT) Yes (rectal) No No
2 Escherichia coli Piperacillin/Tazobactam: R
Ceftazidime: R
Gentamicin: S
Fluroquinolones: R
Meropenem: S (0,5)
Ertapenem: R (2)
Imipenem: S (≤1)
Colistin: S
Ceftazidime/Avibactam: S
Ceftolozan/Tazobactam: S
OXA-48 No, already known at admission (prior to HSCT) Yes (rectal, groin) No No
3 Acinetobacter baumannii Piperacillin/Tazobactam: R
Ceftazidime: R
Gentamicin: R
Fluroquinolones: R
Meropenem: R (> 16)
Imipenem: R (> 8)
Colistin: S
Ceftazidime/Avibactam: R
Ceftozolan/Tazobactam: R
Not detected No, already known at admission (prior to HSCT) Yes (rectal, groin, naso-pharyngealc) Yes (BSI), onset prior to HSCT High dose meropenem, amikacin, colistin Yes: Decolonization of skin, oral and nasal mucosa with octenidine-dihydrochloride
  1. aMinimal inhibitory concentrations (Merlin system) for the carbapenems are shown in the brackets, the unit is mg/L. b In the Escherichia coli isolates OXA-48, KPC, NDM, VIM and IMP-1 were tested. In the Acinetobacter baumannii isolate OXA-23, OXA-48, KPC, NDM, VIM and IMP-1 were tested. cThe nasopharyngeal specimen was not part of the regular CR GNB screening. CR carbapenem-resistant, GNB Gram-negative bacteria, HSCT Hematopoietic stem cell transplantation, BSI Bloodstream infection, R resistant, I intermediate, S susceptible
\